Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19006537 | 1.00 | GABRA3 (0.41) | GABRA3GABRA2GABRA1GABRA5GABRB2 | |
| SCHEMBL5769443 | 0.91 | GABRA1 (0.43) | GABRA3GABRA2GABRA1GABRA5GABRB2 | |
| SCHEMBL20473301 | 0.90 | BRD4 (0.41) | BRD4HDAC6HDAC1 | |
| SCHEMBL19006556 | 0.90 | BRD4 (0.41) | BRD4HDAC6HDAC1 | |
| SCHEMBL20473330 | 0.90 | BRD4 (0.41) | BRD4HDAC6HDAC1 | |
| SCHEMBL22853709 | 0.87 | GABRA1 (0.39) | GABRA3GABRA2GABRA1GABRA5GABRB2 | |
| SCHEMBL26146535 | 0.86 | GABRA1 (0.39) | GABRA3GABRA2GABRA1GABRA5GABRB2 | |
| SCHEMBL26146551 | 0.85 | GABRA1 (0.40) | GABRA3GABRA2GABRA1GABRA5GABRB2 | |
| SCHEMBL21674324 | 0.85 | GABRA1 (0.41) | GABRA3GABRA2GABRA1GABRA5GABRB2 | |
| Remimazolam SCHEMBL23735014 | 0.85 | GABRA1 (0.42) | GABRA3GABRA2GABRA1GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312511-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-11-01 | — | — | US | claimed |
| EP-3363801-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2018-08-22 | — | — | EP | claimed |
| US-20180312511-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2018-11-01 | — | — | US | disclosed |
| EP-3363801-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017101808-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312511-A1 | SHORT-ACTING BENZODIAZEPINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF | GABRA5, GABRA1, GABRA6 | GABRA3 7/4885GABRA2 5/4885GABRA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.